Venlafaxine: In vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2

Abstract

Aims: In order to anticipate drug-interactions of potential clinical significance the ability of the novel antidepressant, venlafaxine, to inhibit CYP2D6 dependent imipramine and desipramine 2-hydroxylation was investigated in human liver microsomes. The data obtained were compared with the selective serotonin re-uptake inhibitors, fluoxefine, sertraline, fluvoxamine and paroxefine. Venlafaxine's potential to inhibit several other major P450s was also studied (CYP3A4, CYP2D6, CYP1A2). Methods: K(i) values for venlafaxine, paroxetine, fluoxetine, fluvoxanfine and sertraline as inhibitors of imipramine and desipramine 2-hydroxylation were determined from Dixon plots of control and inhibited rate data in human hepatic microsomal incubations. The inhibitory effect of imipramine and desipramine on liver microsomal CYP2D6 dependent venlafaxine O-demethylation was determined similarly. Venlafaxine's IC50 values for CYP3A4, CYP1A2 CYP2C9 were determined based on inhibition of probe substrate activities (testosterone 6β-hydroxylation, ethoxyresorufin O-dealkylase and tolbutamide 4-hydroxylation, respectively). Results: Fluoxetine, paroxetine, and fluvoxamine were potent inhibitors of imipramine 2-hydroxylase activity (K(i) values of 1.6 ± 0.8, 3.2 ± 0.8 and 8.0 ± 4.3 μM, respectively; mean ± s.d., n=3), while sertraline was less inhibitory (K(i) of 24.7 ± 8.9 μM). Fluoxetine also markedly inhibited desipramine 2-hydroxylation with a K(i) of 1.3 ± 0.5 μM. Venlafaxine was less potent an inhibitor of imipramine 2-hydroxylation (K(i) of 41.0 ± 9.5 μM) than the SSPIs that were studied. Imipramine and desipramine gave marked inhibition of CYP2D6 dependent venlafaxine O-demethylase activity (K(i) values of 3.9 ± 1.7 and 1.7 ± 0.9 μM, respectively). Venlafaxine did not inhibit ethoxyresorufin O-dealkylase (CYP1A2), tolbutamide 4-hydroxylase (CYP2C9) or testosterone 6β-hydroxylase (CYP3A4) activities at concentrations of up to 1 mM. Conclusions: It is concluded that venlafaxine has a low potential to inhibit the metabolism of substrates for CYP2D6 such as imipramine and desipramine compared with several of the most widely used SSRls, as well as the metabolism of substrates for several of the other major human hepatic P450s.